Company: PMVP
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001140361-25-015610
Chunk: 31

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 31
---
 Strategy, Oncology from July 2017 to June 2019 and was responsible for overseeing global regulatory strategy development for multiple early and late stage oncology assets. Dr. Jalota also served as Senior Director, Global Regulatory Strategy, Oncology from June 2016 to July 2017 and Director and Head of Global Regulatory Strategy, Dermatology and Ophthalmology from January 2014 to June 2016. Prior to joining Bayer HealthCare Pharmaceuticals, Dr. Jalota was employed by Sanofi-Aventis, Forest Laboratories and Procter and Gamble. Dr. Jalota received a B.S. in Pharmacy from Rutgers University, Ernest Mario School of Pharmacy and a Pharm.D. from the University of Florida, College of Pharmacy. Robert Ticktin has served as our General Counsel and Chief Operating Officer since December 2024. Prior to being promoted as our General Counsel and Chief Operating Officer, Mr. Ticktin served as our General Counsel from August 2020 to December 2024. Before joining PMV Pharmaceuticals, from April 2017 to June 2020, Mr. Ticktin was an Associate General Counsel, Corporate at Tesaro, Inc., a development and commercial oncology company (formerly Nasdaq: TSRO), which was acquired by GSK plc, a British multinational pharmaceutical and biotechnology company (NYSE: GSK), in December 2018. Mr. Ticktin was General Counsel of Epirus Biopharmaceuticals (formerly Nasdaq: EPRS), a biosimilar drug development company, from April 2014 to August 2016, and previously served in legal roles of increasing responsibility at Amgen from 2004 to 2014. Mr. Ticktin received a B.A. in Economics, Computer Science from The Ohio State University and a J.D. from Fordham University School of Law.

18

TABLE OF CONTENTS

EXECUTIVE COMPENSATION Summary Compensation Table Our named executive officers for fiscal year ended December 31, 2024, which consist of our principal executive officer and the next two most highly compensated executive officers, are:

| • | David H. Mack, Ph.D., our President, Chief Executive Officer and Director; |

| • | Michael Carulli, our Chief Financial Officer; and |

| • | Deepika Jalota, Pharm.D., our Chief Development Officer. |

The following table sets forth information regarding the compensation reportable for our named executive officers for fiscal 2023 and 2024.

| Name and Principal Position                     |